Clinical Trial Update: Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD [Phase 3]

View source ↗

Summary

Phase 3 pivotal study update on RGX-314 gene therapy for neovascular age-related macular degeneration (nAMD), with recruitment ongoing under AbbVie.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration
• Choroidal Neovascularization
• Neovascular Age-related Macular Degeneration

Drugs mentioned

• RGX-314

Snippet

Sponsor: AbbVie | Conditions: AMD, nAMD | Phase 3 | Status: RECRUITING